🔍 See what insiders are buying — free 7-day trial, no credit card required.
Get started →
NVO
NYSE
🇺🇸 US
Novo Nordisk A/S
Pharmaceuticals
34Score
DipBuster Score™
$45.16
$1.44 (-3.09%)
Live price · Source: Yahoo
52-Week Position
$35.12
35% of range
$64.16
Beta
0.349
Low vol
Dividend
—
no income
Mkt Cap
N/A
total value
Mkt CapN/A
P/EN/A
DividendNone
Beta0.349
52W High$64.16
52W Low$35.12
DipBuster Brief
Key signals at a glance
Zone: Buy Zone
Neutral
Mid-Range Position (35% of 52-Week Range)
The stock sits in the middle of its annual range — no extreme dip opportunity, but also not overextended.
Neutral
Earnings Data Unavailable
P/E ratio could not be determined — this is common for early-stage, loss-making, or recently-listed companies.
Valuation
P/E Ratio—
Mkt CapN/A
52W Position35% of range
EV/EBITDA—
Cash Flow
FCF Yield—
FCF / Share
Op. Cash Flow—
Margins
Gross Margin—
Op. Margin—
Net Margin—
Balance Sheet
Cash—
Total Debt—
Net Cash—
Dividend
Yield—
Annual / shNone
Beta0.349
🔒
FCF, margins & balance sheet data are hidden — create a free account to see them.
🕵️ Insiders
📊 Valuation
💰 Dividends
📰 News
🤖 AI Analysis
Loading insider data...
Valuation
P/E RatioN/A
Market CapN/A
Beta0.349
Dividend/yrNone
52W High$64.16
52W Low$35.12
52-Week Range
$35.12Now$64.16
35% through annual range
From 52W High−29.6%
From 52W Low+28.6%
📖 Plain English Summary
Novo Nordisk A/S is at 35% of its 52-week range. Beta 0.349 — tends to move less than the market.
🏦 Analyst Price Target
Loading…
🎯 Analyst Revenue & EPS Estimates
Loading estimates…
🔄 Peer Comparison
Loading peers…
Loading dividend data…
Latest news for NVO
🟢 Bullish
⬜ Neutral
🔴 Bearish
🤖
DipBuster AI Analysis — NVO
Heuristic · balance sheet, insider filings, price data, academic research
Novo Nordisk A/S — DipBuster Score 34/100
Graham value assessment, NCAV analysis, price zones...
Insider signals, cluster detection, risk factors...
Track Novo Nordisk A/S free
Add NVO to a watchlist, set insider-buy and price alerts, and get the full financial picture — free account, no card.
Sponsored · FCA Regulated Broker
Hargreaves Lansdown
UK's #1 investment platform. ISA, SIPP, GIA. FCA regulated since 1981.
Capital at risk. Your investments can go down as well as up. Disclaimer
DipBuster Score™ Breakdown
Value & P/E
0/30
Dip Position
26/25
Momentum & Volume
3/25
Quality & Size
5/10
Insider Activity
0/10
🎯 Dip Buyer Signal
38
/100 · NEUTRAL
dip depth
21/25
oversold rsi
7/25
mean reversion
10/15
insider zone
0/25
capitulation
0/10
Technical signal only. Not financial advice.
Quick Take
⚪
Not a Dip
DipBuster Score: 34/100
📉
Weak momentum — price has been struggling lately.
Company Profile
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends througho…
Sector
Pharmaceuticals
Market
🇺🇸 US
CEO
Maziar Mike Doustdar
Staff
68,794 employees
Website